Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
Xi DingWei-Jing ZhangRui YouXiong ZouZhi-Qiang WangYan-Feng OuyangLan PengYou-Ping LiuChong-Yang DuanQi YangChao LinYu-Long XieSi-Yuan ChenYong-Long LiuChen-Mei GuRuo-Qi XiePei-Yu HuangMing-Huang HongYi-Jun HuaMing-Yuan ChenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Camrelizumab plus apatinib had promising antitumor activity in patients with refractory recurrent/metastatic NPC who failed first-line therapy. Moderate to severe TRAEs were experienced by 58.6%, including nasopharyngeal necrosis associated with local recurrence and a history of reirradiation.